CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio. OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham are part of the Zacks Screen of the ...
Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $130 from $78 and keeps a Buy rating on the shares. The firm is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback